G
-protein-coupled receptors (GPCRs) play an essential part in mediating signalling in the cells of many organisms. This process is primarily controlled by activation-dependent interactions of GPCRs with three protein families: heterotrimeric guanine-nucleotide-binding proteins (G proteins), GPCR kinases (GRKs) and arrestins. Until now, the only complete structure 1 of a GPCR complex was that of the β 2 -adrenergic receptor bound to the G protein Gs, solved in 2011. In this issue, Kang et al. 2 (page 561) present the second structure of a GPCR complex, in this case the GPCR rhodopsin bound to arrestin-1.
The binding of a GPCR to a G protein results in the activation and subsequent regulation of downstream effector enzymes that modulate levels of 'second messenger' molecules such as cyclic AMP and calcium. By contrast, the interaction of a GPCR with a GRK promotes phosphorylation of the receptor, which in turn facilitates arrestin binding. This turns off G-protein signalling, a process called desensitization, and promotes cellular internalization of the receptors and arrestin-mediated signalling. The dynamics of these protein-protein interactions are complex and incompletely understood.
The best-characterized GPCR signalling pathway regulates the process of phototransduction in rod cells in the retina of the eye. This pathway involves rhodopsin, the G protein transducin and the effector enzyme cGMP phosphodiesterase (Fig. 1a) . Phototransduction is highly regulated by a GRK (GRK1) and an arrestin (arrestin-1); mutations in either of these proteins can lead to a visual defect called Oguchi disease. Rhodopsin was the first GPCR to be crystallized in its basal state 3 as well as in various activated conformations [4] [5] [6] . Although some structural insight into the binding of G proteins 5, 6 and arrestins 7 to rhodopsin has been gained by using peptides co-crystallized with the receptor, Kang and colleagues' structure of the full protein complex is a significant advance. Solving the X-ray structure of a rhodopsinarrestin complex proved challenging and required a team of 72 investigators across 25 institutions, who used various tricks to obtain diffractable crystals. First, the two proteins were mutated to aid the formation of active conformations. For rhodopsin, these mutations (E113Q and M257Y) yielded a conformation that was constitutively active even in the absence of a bound chromophore (a colour-determining chemical group, such as all-trans-retinal, which typically activates rhodopsin). For arrestin, the researchers mutated three adjacent amino-acid residues in a region that stabilizes the basal conformation and largely overcomes the need for the receptor to be phosphorylated to bind arrestin 8 . The authors were unable to generate a stable rhodopsin-arrestin binary complex (one formed through non-covalent binding). Instead, they purified and crystallized a fusion protein in which arrestin was fused to the carboxy terminus of rhodopsin through a 15-residue linker. This fusion protein also included the enzyme T4 lysozyme at the amino terminus of rhodopsin -this facilitates crystallization without altering the structure of the complex. Finally, because the crystals were small and diffracted to 6-8 ångström in synchrotron experiments, the authors used serial femtosecond X-ray laser crystallography, performed at the SLAC National Accelerator Laboratory in Menlo Park, California, to capture diffraction data for the crystals. This provided enough data to solve a structure of the complex with resolution limits of 3.3-3.8 Å.
The structure reveals multiple points of contact between rhodopsin and arrestin, as well as structural changes in both proteins (Fig. 1b) . The primary interface between the proteins involves the finger loop of arrestin (which connects β-strands V and VI in arrestin and adopts an α-helical conformation when bound), which interacts with three regions of rhodopsin: intracellular loop (ICL) 1, the N-terminal region of helix 8, and the C-terminal region of transmembrane (TM) 7. Additional interactions include several arrestin loops: the middle and lariat loops bind to ICL2 on rhodopsin, the back loop binds to TM5, and β-strand VI binds to TM5, TM6 and ICL3.
The authors' basic model proposes that rhodopsin uses multiple structural elements including TM7 and helix 8 to initially recruit arrestin, resulting in a rotation of approximately 20 o between the N and C domains of arrestin; this opens a cleft to accommodate rhodopsin's ICL2. Indeed, a similar rotation between the N and C domains has been observed 9 in a preactivated truncated form of arrestin-1 and in β-arrestin-1 (also known as arrestin-2) when bound to a phosphorylated STRUCTURAL BIOLOGY
Arresting developments in receptor signalling
The first crystal structure of a G-protein-coupled receptor in complex with an arrestin protein provides insight into how the signalling pathways activated by these receptors are switched off through desensitization. See Article p.561 Figure 1 | The phototransduction pathway. a, The signalling pathway involving the G-protein-coupled receptor rhodopsin is initiated when light activation induces rhodopsin to form meta II rhodopsin, which interacts with the G protein transducin (Gt) to activate the effector enzyme cGMP phosphodiesterase. This pathway ultimately leads to a rapid visual response in rod cells. Meta II is then phosphorylated by the protein kinase GRK1 to yield P-meta II, which promotes interaction with the protein arrestin-1 to preclude further binding of Gt. P-meta II recycles by losing its bound chromophore (all-trans-retinal) to become P-opsin (not shown), which promotes arrestin-1 dissociation and dephosphorylation of the receptor. Opsin then binds the chromophore 11-cis-retinal to yield rhodopsin. Each of the individual proteins in this pathway (rhodopsin, meta II, opsin, Gt, GRK1 and arrestin-1) have been crystallized. b, Kang et al. 2 provide the first crystal structure of a protein complex in this pathway, that of activated rhodopsin (blue) bound to arrestin-1 (red). Sections of arrestin-1 involved in the interface with rhodopsin are shown in yellow. The carboxy terminus of rhodopsin, which is phosphorylated by GRK1, is shown in purple. Rhodopsin is depicted in a phospholipid bilayer. PAT R I C K F. S U L L I VA N O f all complex human illnesses, major depressive disorder (MDD) has arguably proved the trickiest to understand. Despite decades of research, there is little certainty about its biological basis, in part because genetic clues to its aetiology have been hard to find 1 . The combination of relatively high prevalence and relatively low heritability seems to indicate that MDD does not lend itself to genetic analysis, although the genetic dissection of type 2 diabetes mellitus, which has a similar prevalence and heritability, has been much more productive. On page 588 of this issue, the CONVERGE consortium 2 identifies the first two long-awaited genetic associations for MDD.
Our ignorance about MDD is in marked contrast to its impact on people and public health 3 . The disease is common, costly and associated with high rates of morbidity and mortality. As such, it stands to reason that this research is exciting for those who study MDD. But it also exemplifies a sometimes neglected issue -how an informed approach to improving the definition of a complex illness can lead to success where other approaches have failed.
Why is defining MDD so complicated? Sadness is normal and integral to the human condition. However, much too frequently, sadness becomes pervasive, persistent, unshakable and associated with signs and symptoms characteristic of MDD, such as changes in sleeping habits, appetite and cognition, and the onset of suicidal tendencies. But where should we draw the line between normality and pathology? This question is echoed throughout medicine, for example when using normal fasting blood glucose levels to delineate normal physiology from that of type 2 diabetes, or when separa ting normal blood pressure from hypertension. The difference is that the measures for these latter two conditions are more objective than those for assessing 'sadness' , and the consequences of each disease more readily ass ess ed.
There is no laboratory test that will help us to know when sadness becomes MDD. The CONVERGE consortium authors reasoned that the core issue hampering the discovery of MDD-associated genes is heterogeneity -in a group of people who all have the same MDD symptoms, the aetiology of the MDD may in fact be different. Some people might have a highly genetic form of the disease, whereas in others, MDD may be brought on by environmental factors such as poverty, physical or sexual abuse, or an unhealthy lifestyle. Still others may have a primary problem such as alcoholism, of which MDD is a secondary consequence. This long-held concept of heterogeneity has made defining 'true' MDD something of a holy grail.
The researchers made a set of intelligent decisions when defining who to study. They reasoned that more-severe cases would have a clearer and less-complex genetic signal -an approach widely used in human genetics to minimize heterogeneity in complex illnesses.
Unlike more-inclusive approaches 4 , the consortium authors implemented several measures that they thought would maximize their chances of success. They worked in China, where the prevalence of MDD is lower than that in the United States or Europe, studied only women and selected relatively severe cases, in which the women had experienced two or more episodes of MDD, using psychiatric in patient and outpatient facilities. Un usually, they genotyped their samples using low-coverage whole-genome sequencing (genotyping determines the identity of genetic variations across the genome). They identified two regions in which genetic changes, or variants, are associated with MDD -one near the SIRT1 gene and the other in an intron (a nonprotein-coding region) of the gene LHPP.
The typical approach to genotyping in human genetics is to use an array containing a fixed set of between 500,000 and 1 million genetic markers -DNA variants at known chromosomal locations. To my knowledge, this is the only published study in which genotyping involved low-coverage sequencing of the whole genome. Because of decreases in the costs of genotyping arrays, it may be one of the last. The authors' low-coverage sequencing had relatively high error rates -around 2% of the genetic variants that they identified could not be replicated with a different method, compared with less than 0.5% for an inexpensive array. Moreover, despite their wish to gain traction on MDD-causing genetic associations that have yet to be described in China, the two variants that they found have been in standard databases for a decade. This is because genetic variants such as these, which are common in China, are evolutionarily old, and so likely to be found across the globe. Wisely, the authors receptor peptide 10 . Kang et al. extensively validated their rhodopsin-arrestin structural model by using double electron-electron resonance, hydrogen-deuterium exchange mass spectrometry, cell-based rhodopsinarrestin interaction assays, and site-specific disulfide cross-linking experiments.
Kang and colleagues' study provides insight into the interactions between GPCRs and arrestins, but much remains to be learned. We clearly need the structures of more GPCR complexes with G proteins, arrestins and GRKs, including complexes of such proteins with the same GPCR -for example, the β 2 -adrenergic receptor in complex, separately, with Gs, GRK2 and β-arrestin-1, or rhodopsin in complex with transducin and GRK1 to complement the arrestin-1 structure. Such studies will reveal whether these three classes of protein have specific preferences for particular receptor conformations, and should facilitate the development of compounds that might serve as selective modulators of specific GPCR signalling pathways. This would be an important step in helping to treat the many diseases that are mediated by GPCR signalling pathways, which are currently the target for approximately 40% of the pharmaceuticals on the market. ■ 
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